ReviewJournal of obesity & metabolic syndrome2025
Crosstalk between Epigenetics and Autophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Review in Journal of obesity & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- β-Hydroxybutyrate upregulates hepatic histone β-hydroxybutyrylation modification, promotes the expression of PPARα, and alleviates the hepatic steatosis in MASLD.Clinical epigenetics · 2026Article
- Pathophysiology, development, and mortality of major non-communicable diseases in metabolic dysfunction-associated steatotic liver disease: A comprehensive review.International journal of biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is one of the most common causes of liver dysfunction worldwide, posing a significant economic burden. However, our understanding of the cellular and molecular mechanisms underlying the pathogenesis of MASLD is in its early stages. Over the last two decades, epigenetic mechanisms and autophagy have emerged as two independent phenomena that control cellular and molecular processes in health and disease. Epigenetic events and defects in autophagy have been linked with the pathogenesis of MASLD and metabolic dysfunction-associated steatohepatitis (MASH) in cellular studies, mouse models, and human research. However, the connection between epigenetic mechanisms and autophagy regulation in MASLD and MASH pathogenesis remains unclear. This review highlights the importance of epigenetic modifications and their regulatory switches in controlling downstream pathways that significantly impact metabolic disease pathogenesis. We also review the need to identify key epigenetic factors regulating autophagy in MASLD and MASH pathogenesis. Such insights could aid the development of novel strategies to restore autophagy and improve disease outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.